#Switzerland #Lausanne #Xsensio #Lab-on-Skin #Clinical Biosensing

Xsensio Secures $7M in Oversubscribed Series A Funding for Advanced Biosensing

On March 3, 2026, Xsensio SA, a pioneering Swiss deep-tech company, announced a significant milestone in its journey toward reimagining health monitoring technology. The company has successfully closed a $7 million Series A financing round, which was oversubscribed, showcasing robust interest from investors and marking an exciting phase for their innovative work in near real-time continuous biochemical monitoring.

A New Era in Biosensing Technology

Xsensio's flagship product, the Lab-on-Skin© device, is at the forefront of wearable biosensing technology. This cutting-edge gadget enables simultaneous and continuous monitoring of various biochemical biomarkers, an innovation that could revolutionize how healthcare professionals access and interpret health data.

The financing round was led by WI Harper, a notable venture capital firm based in San Francisco. It also saw participation from Privilège Ventures, the European Innovation Council, and other private investors spanning the United States, Europe, and Asia. This diverse investment base underscores the global appeal and potential of Xsensio's technology.

Transformative Funding Goals

The funds raised are intended to accelerate the development and clinical validation of the Lab-on-Skin© platform. By enhancing the clinical decision-making capabilities of healthcare professionals, this portable biosensing system strives to facilitate immediate and informed responses to patient needs both in hospitals and other healthcare settings. As Esmeralda Megally, CEO of Xsensio, noted, “This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments.” With access to real-time biochemical data, clinicians can significantly improve patient monitoring and management.

Forging Powerful Partnerships

In tandem with the funding announcement, Xsensio revealed a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This alliance aims to leverage TI's expertise in CMOS integration and manufacturing scalability, crucial steps in advancing Xsensio's biosensing systems. Adrian Ionescu, CTO of Xsensio, emphasized the importance of this partnership, stating, “By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact but also for reliable, cost-effective deployment.”

This collaboration positions Xsensio to push the boundaries of wearable healthcare technology, addressing numerous challenges in the current healthcare framework and enhancing operational efficiencies within clinical environments.

Recognition and Future Aspirations

Xsensio's work has garnered significant attention; in 2025, the company was recognized by TIME as one of the World's Top HealthTech Companies. With the funding secured and strategic partnerships in place, Xsensio is poised to redefine health monitoring by establishing a new category in wearable biosensing.

As Wilson Wu, Partner at WI Harper, stated in his remarks about the investment, “Continuous biochemical monitoring represents a major shift from intermittent measurements to real-time insight, and Xsensio is uniquely positioned to lead this transformation.” The implications of this technology could be profound, offering the possibility of personalized and preventive healthcare accessible to a wide array of patients.

With its innovative technology and strong financial backing, Xsensio SA is undoubtedly on a trajectory to change how healthcare professionals interact with health data, making continuous monitoring a standard practice in health management.

For more information on Xsensio and its groundbreaking products, visit their website at www.xsensio.com.